Latest news with #NBE
Zawya
15 hours ago
- Business
- Zawya
Egypt: USD/EGP exchange slightly down on Tuesday
Arab Finance: The exchange rate between the US dollar and the Egyptian pound recorded EGP 49.36 for buying and EGP 49.46 for selling at the National Bank of Egypt (NBE) and Banque Misr on Tuesday. The US dollar traded at EGP 49.37 for purchasing and EGP 49.47 for selling at the Commercial International Bank Egypt (CIB). At the Suez Canal Bank, the USD registered EGP 49.40 for buying and EGP 49.50 for selling. Meanwhile, it declined EGP 49.35 for purchasing and EGP 49.45 for selling at the United Bank. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
&w=3840&q=100)
Business Standard
17 hours ago
- Business
- Business Standard
Institutional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Anthem Biosciences IPO subscription status: Non-institutional investors (NIIs) were driving the demand for the initial public offering (IPO) of Anthem Biosciences on the final day of subscription. The participation from the qualified institutional buyers (QIBs), and retail investors was also encouraging as the public issue garnered bids for 48,76,15,180 equity shares against 4,40,70,682 on offer, resulting in an oversubscription of 11:06 times till 12:42 PM on Wednesday, July 16, showed the NSE data. Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes. Anthem Biosciences IPO grey market premium (GMP) today The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities. Anthem Biosciences IPO review Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile. Anthem Biosciences IPO details The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820. As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18. Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025. Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager. About Anthem Biosciences Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
&w=3840&q=100)
Business Standard
20 hours ago
- Business
- Business Standard
Intuitional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Anthem Biosciences IPO subscription status: Non-institutional investors (NIIs) were driving the demand for the initial public offering (IPO) of Anthem Biosciences on the final day of subscription. The participation from the qualified institutional buyers (QIBs), and retail investors was also encouraging as the public issue garnered bids for 48,76,15,180 equity shares against 4,40,70,682 on offer, resulting in an oversubscription of 11:06 times till 12:42 PM on Wednesday, July 16, showed the NSE data. Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes. Anthem Biosciences IPO grey market premium (GMP) today The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities. Anthem Biosciences IPO review Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile. Anthem Biosciences IPO details The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820. As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18. Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025. Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager. About Anthem Biosciences Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
Indian Express
3 days ago
- Politics
- Indian Express
SC to hear on Aug 3 pleas seeking transparency in NEET-PG Exam evaluation process
The Supreme Court on Monday fixed August 3 for hearing pleas raising concerns over the transparency of the NEET-PG examination process, particularly with regard to the release of answer keys and evaluation protocols. A bench comprising justices K Vinod Chandran and NV Anjaria briefly heard pleas on the issues. One of the pleas, filed through lawyer Tanvi Dubey, challenges the opaque nature of the evaluation system and seeks multiple directions to the National Board of Examinations (NBE), the authority responsible for conducting NEET-PG. The plea sought release of question papers and answer keys to candidates and disclosure of correct and incorrect questions as assessed. It also sought a direction for revaluation or rechecking in cases of score discrepancies. The plea also sought a direction to enable candidates to challenge disputed questions or answers and institution of transparent evaluation mechanisms for current and future NEET-PG examinations. The plea alleged a lack of transparency and said it undermined the credibility of such a crucial examination and adversely impacted the rights of candidates.
The Hindu
3 days ago
- Politics
- The Hindu
Supreme Court to hear on August 3 pleas seeking transparency in NEET-PG Exam evaluation process
The Supreme Court on Monday (July 14, 2025) fixed August 3 for hearing pleas raising concerns over the transparency of the NEET-PG examination process, particularly regarding the release of answer keys and evaluation protocols. A bench comprising justices K. Vinod Chandran and N.V. Anjaria briefly heard pleas on the issues. One of the pleas, filed through lawyer Tanvi Dubey, challenges the opaque nature of the evaluation system and seeks multiple directions to the National Board of Examinations (NBE), the authority responsible for conducting NEET-PG. The plea sought the release of question papers and answer keys to candidates, and the disclosure of correct and incorrect questions as assessed. It also sought a direction for revaluation or rechecking in cases of score discrepancies. The plea also sought a direction to enable candidates to challenge disputed questions or answers and the institution of transparent evaluation mechanisms for current and future NEET-PG examinations. The plea alleged a lack of transparency and said it undermined the credibility of such a crucial examination and adversely impacted the rights of candidates.
